BridgeMD
Zanubritnib and anti-MAG neuropathy
EU CTIS ID: 2025-523091-23-00
What this study is testing
To investigate whether 12 months zanubrutinib treatment lead to an improvement of at least 1 point in at least 2 neurological scales, such as Overall Neuropathy Limitations Scale (ONLS), INCAT disability, INCAT sensory sum scores (ISS), MRC sum score, I-RODS functional score.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- ● Age ≥18 years; ● diagnosis of anti-MAG antibody polyneuropathy; ● diagnosis of anti-MAG antibody polyneuropathy; ● IgM monoclonal protein underlying MGUS, Waldenstrom macroglobulinemia (based on the WHO definition of clonal lympho-plasmocytes ≥10%), marginal zone lymphoma, chronic lymphocytic leukemia or low- grade lymphoma not otherwise specified; ● Presence of anti MAG antibodies (titer ≥ 7.000 BTU)
You likely can't join if
- ● Previous treatment with BTK inhibitors ● Aggressive non-Hodgkin lymphoma or IgM multiple myeloma ● Evidence of moderate or severe motor nerve axonal damage ● ECOG >3 ● Requiring ongoing therapy with strong or moderate cytochrome P450 3A (CYP3A) inducer. Use of strong/moderate CYP3A inducers within 14 days prior to the first dose of zanubrutinib (see Drug-interaction section). ● creatinine clearance <30mL/min
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.